Efficacy of hepatectomy-predominant treatment on stage IIIA hepatocellular carcinoma: A report of 108 cases

Chinese Journal of Cancer

Volumn 28, Issue 3, 2009, Pages 230-233

  Zhong, Chong ^a,b   Guo, Rong Ping ^a,b   Chen, Min Shan ^a,b   Wei, Wei ^a,b   Chen, Zhi Yuan ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Efficacy; Hepatectomy; Liver neoplasm; Survival rate; Transcatheter arterial chemoembolization

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; HEPATITIS B SURFACE ANTIGEN; MITOMYCIN C;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PAIN; SURVIVAL TIME; TUMOR VOLUME; VOMITING;

EID: 70349656246     PISSN: 1000467X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and non-surgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan [J]. Hepatology, 2000,32(6):1224-1229.
2. Tang ZY. Recurrence and metastasis - a focal point of the researches on primary liver cancer. [J]. Chin J Hepatobiliary Surg, 1999,5(1):3-5.
3. Li GH, Li JQ, Zhang YQ, et al. Results of hepatic resection for 600 cases with primary liver cancer [J]. Zhonghua Zhong Liu Za Zhi, 1995,17(2):125-127.
4. Guo RP, Chen MS, Lin XJ, et al. Significance of removing portal vein tumor thrombus and TACE in improving outcome of resection for primary liver cancer with portal vein tumor thrombus [J]. Chin J Hepatobiliary Surg, 2000,6(5):374-376.
5. Li JQ, Zhang YQ, Zhang WZ, et al. Evaluation of chemoembolization as an adjuvant therapy for primary liver carcinoma after surgical resection [J]. Zhonghua Zhong Liu Za Zhi, 1994,16(5):387-389.
6. International Union Against Cancer (UICC). Sobin LH, Wittekind C, eds. TNM classification of malignant tumors [M]. 6th edition. New York: Wiley-Liss, 2002:81-83.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma [J]. Hepatology, 2005,42(5):1208-1236.
8. Chen XP, Zhang ZW, Yang JM, et al. 2004 guidelines for surgical treatment of primary hepatocellular carcinoma [J]. Chin J Hepatobiliary Surg, 2005,11(10):698-700.
9. Fan J, Tang ZY, Wu ZQ, et al. The effects of portal vein microscopic and macroscopic tumor thrombi on post-operation patients with hepatocellular carcinoma [J]. Zhonghua Wai Ke Za Zhi, 2005,43(7):433-435.
10. Li BK, Cui BK, Yuan YF, et al. Evaluation of new TNM staging system for hepatocellular carcinoma after hepatectomy [J] Ai Zhen, 2005,24(7):769-773.
11. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials [J]. Aliment Pharmacol Ther, 2006,23(11):1535-1547.
12. Wu MC. The currence and future of surgical combination treatment for hepatocellular carcinoma [J]. Chin J Hepatobiliary Surg, 2006,12(1):1-4.
13. Guo RP, Zhong C, Shi M, et al. Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma [J]. J Cancer Res Clin Oncol, 2006,132(9):547-555.
14. Shi M, Guo RP, Lin XJ, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial [J]. Ann Surg, 2007,245(1):36-43.
15. Schafer DF, Sorrell MF. Hepatocellular carcinoma [J]. Lancet, 1999,353(9160):1253-1257.
16. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival [J]. Hepatology, 2003,37(2):429-442.
17. Schwartz JD, Schwartz M, Mandeli J, et al. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomized clinical trials [J]. Lancet Oncol, 2002,3(10):593-603.
18. Cheng HY, Xu W, Xu AM, et al. Evaluation of transcatheter arterial chemoembolization in the prevention of postoperative recurrence in 1630 patients with hepatocellular carcinoma [J]. Zhonghua Zhong Liu Za Zhi, 2005,27(10):626-628.
19. Liu YY. Overview of transcatheter arterial chemoembolization for hepatocellular carcinoma [J]. Zhonghua Wai Ke Za Zhi, 2004,42(5):257-259.
20. Ren ZG, Lin ZY, Xia JL, et al. Effect of postoperative transcatheter arterial chemoembolization on hepatocellular carcinoma patients with residual tumor [J]. Zhonghua Zhong Liu Za Zhi, 2004,26(2):116-118.
21. Tanaka K, Shimada H, Togo S, et al. Use of transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection [J]. Hepatogastroenterology, 1999,46(26):1083-1088.
22. Asahara T, Itamoto T, Katayama K, et al. Adjuvant hepatic arterial infusion chemotherapy after radical hepatectomy for hepatocellular carcinoma - results of long-term follow-up [J]. Hepatogastroenterology, 1999,46(26):1042-1048.
23. Kwok PC, Lam TW, Lam PW, et al. Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma [J]. J Gastroenterol Hepatol, 2003,18(4):450-455.